制造业是实体经济的根基，是经济高质量发展的核心支撑。山东新华医疗器械股份有限公司（以下简称"新华医疗"）凭借深厚的历史底蕴与永不停歇的创 新精神，在机械制造板块持续书写传奇篇章。从胶东抗日根据地中诞生的简陋手工作坊，到如今成长为国内医疗器械、制药装备领域的双龙头企业，八十 余载的奋斗历程，生动诠释了技术创新如何成为企业发展的核心驱动力，更彰显了新华医疗在推动行业进步中的重要使命与担当。 放射诊疗设备是新华医疗的优势领域。早在1969年，面对国内放射治疗领域的空白，新 华医 疗成功研制出中国第一台放 射治疗产品 ——钴-60治疗机， 为我国放疗事业奠定坚实基础。此后，公司持续加大研发投入，不断创新突破。全球首发的智能环形在线自适应放疗系统，采用突破性环形机架结构，有 效解决了传统放疗设备在肿瘤定位、剂量控制和治疗效率等方面的不足。 目前，新华医疗已发展成为国内规模最大的放射治疗设备研制生产基 地，掌 握全系列医用电子直线加速器以及大孔径C T、诊断D R等产品的核心技术， 打破国际垄断，产品技术水平达 到世界一流 水准。在近期中国医学装备协会第九批优秀国产医疗设备产品遴选中，新华医疗的XH A600E医用电子直 ...

Group 1 - The core business of the company includes the manufacturing and sales of medical devices and pharmaceutical equipment, as well as providing medical services and trade [2] - The company is a leading entity in the Chinese medical device industry, holding several key positions in industry associations and has developed innovative products such as the world's first peracetic acid low-temperature sterilizer [2] - As of the first quarter of 2025, the company reported a revenue of 2.308 billion yuan, a year-on-year decrease of 8.74%, and a net profit of 160 million yuan, down 23.97% [3] Group 2 - The company's current rolling price-to-earnings (PE) ratio is 14.22, significantly lower than the industry average of 49.10 and the industry median of 36.43 [1][3] - The total market capitalization of the company is 9.118 billion yuan, ranking it 33rd in the medical device industry based on PE ratio [1] - As of the first quarter of 2025, 11 institutions hold shares in the company, with a total holding of 266.514 million shares valued at 4.283 billion yuan [1]

Group 1 - The core viewpoint of the articles highlights the performance and market position of Xinhua Medical, noting its stock price increase and market capitalization [1] - As of April 1, Xinhua Medical's closing price was 16.41 yuan, with a PE ratio of 14.38 times, significantly lower than the industry average of 46.46 times [1][2] - The company ranks 29th in the medical device industry based on PE ratio, indicating a relatively undervalued position compared to its peers [1][2] Group 2 - Xinhua Medical reported a revenue of 74.23 billion yuan for the third quarter of 2024, reflecting a year-on-year growth of 1.45% [1] - The net profit for the same period was 6.17 billion yuan, with a year-on-year decrease of 6.63%, and a gross profit margin of 26.31% [1] - The company is a leading manufacturer in infection control equipment and has a strong position in the domestic market for medical electronic linear accelerators [1]

合作伙伴征集：2025全球手术机器人大会 报名：首届全球眼科大会 | 暂定议程 报名：首届全球心血管大会 | 奖项报名倒计时 报名：首届全球骨科大会 | 奖项报名倒计时 2025年3月15日上午，2025中国医学装备大会在重庆悦来国际会议中心成功召开。相关政府部门领导、知名院士、医疗机构专家，研发生产企业、高校、科 研院所、投融资机构负责人等嘉宾出席大会。 中国医学装备协会理事长 侯岩介绍， 2024年中国医学装备市场规模达到 1.35万亿 元，同比增长 6％ 左右 。据了解，目前我国已形成22个大类1100多个 品类的产品体系，是世界上产品类别和品种最齐全的国家之一，产品广泛服务于临床应用，覆盖卫生健康各个领域。 目前大会已圆满落幕。本届展会中，哪些企业凭借创新亮相引起了行业关注？又有哪些前沿产品和技术成为焦点？思宇将全面回顾展会精彩亮点，供各位读 者参考。 # 美敦力 美敦力在本届大会上展出 近80款 全球创新产品， 包括 全球首发的PulseSelect一次性心脏脉冲场消融导管 ，以及多款前沿技术产品， 其中不乏首次展出及近 期获批的产品和技术。 其中包括中国首款获批的 PulseSelect一次性心脏 ...